Additionally, a proof-of-concept clinical study further confirmed immune activation in ovarian cancers treated with olaparib and the anti-PD-L1 antibody durvalumab regardless of their BRCA status, highlighted by increased IFN-γ production and tumor-infiltrating lymphocytes (Lampert et al. 2020). This evidence concerns the gene CD274 and ovarian carcinoma.